Product nameAnti-PAX4 antibody
See all PAX4 primary antibodies
DescriptionRabbit polyclonal to PAX4
Tested applicationsSuitable for: IHC-P, ELISA, WBmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat, Dog
- Jurkat cell lysate; Human intestinal tissue; Human kidney tissue
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.09% Sodium azide
Constituents: 2% Sucrose, PBS
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab42450 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||Use at an assay dependent concentration.|
|WB||Use a concentration of 0.5 - 2 µg/ml. Detects a band of approximately 42 kDa (predicted molecular weight: 37 kDa). Good results were obtained when blocked with 5% non-fat dry milk in 0.05% PBS-T.|
FunctionPlays an important role in the differentiation and development of pancreatic islet beta cells. Transcriptional repressor that binds to a common element in the glucagon, insulin and somatostatin promoters. Competes with PAX6 for this same promoter binding site. Isoform 2 appears to be a dominant negative form antagonizing PAX4 transcriptional activity.
Involvement in diseaseDefects in PAX4 are a cause of noninsulin-dependent diabetes mellitus (NIDDM) [MIM:125853]; also known as diabetes mellitus type 2 or maturity-onset diabetes. NIDDM is characterized by an autosomal dominant mode of inheritance, onset during adulthood and insulin resistance.
Genetic variations in PAX4 are associated with susceptibility to insulin-dependent diabetes mellitus (IDDM) [MIM:222100]. IDDM normally starts in childhood or adolescence and is caused by the body's own immune system which destroys the insulin-producing beta cells in the pancreas. Classical features are polydipsia, polyphagia and polyuria, due to hyperglycemia-induced osmotic diuresis.
Defects in PAX4 are a cause of susceptibility to diabetes mellitus ketosis-prone (KPD) [MIM:612227]. KPD is an atypical form of diabetes mellitus characterized by an acute initial presentation with severe hyperglycemia and ketosis, as seen in classic type 1 diabetes, but after initiation of insulin therapy, prolonged remission is often possible with cessation of insulin therapy and maintenance of appropriate metabolic control. Metabolic studies show a markedly blunted insulin secretory response to glucose, partially reversible with the improvement of blood glucose control. Variable levels of insulin resistance are observed, especially in obese patients. Pancreatic beta-cell autoimmunity is a rare finding.
Defects in PAX4 are the cause of maturity-onset diabetes of the young type 9 (MODY9) [MIM:612225]. MODY is a form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.
Sequence similaritiesBelongs to the paired homeobox family.
Contains 1 homeobox DNA-binding domain.
Contains 1 paired domain.
- Information by UniProt
- KPD antibody
- MGC129960 antibody
- MODY9 antibody
Ab42450 at 4µg/ml staining human PAX4 in human epithelial cells of intestinal villus by immunohistochemistry, parafin embedded human intestine tissue.
Ab42450 at 4µg/ml staining human PAX4 in epithelial cells of renal tubule by immunohistochemistry, parafin embedded human kidney tissue.
Anti-PAX4 antibody (ab42450) at 0.5 µg/ml + Jurkat cell lysate at 10 µg
HRP conjugated anti-Rabbit IgG at 1/50000 dilution
Developed using the ECL technique.
Predicted band size: 37 kDa
Observed band size: 42 kDa why is the actual band size different from the predicted?
Additional bands at: 58 kDa. We are unsure as to the identity of these extra bands.
Gel concentration 12% Tris-glycine
This product has been referenced in:
- Zhang L et al. KIT is an Independent Prognostic Marker for Pancreatic Endocrine Tumors: A Finding Derived From Analysis of Islet Cell Differentiation Markers. Am J Surg Pathol : (2009). IHC-P ; Human . Read more (PubMed: 19574886) »